Gen-Probe outside Roche, Chugai merger
This article was originally published in Clinica
Executive Summary
Chugai Pharmaceutical's US diagnostics and blood screening unit, Gen-Probe, is to be spun off following the Tokyo company's acquisition by Switzerland's Roche Holding. The purchase of a majority holding in Chugai, announced last week, is expected to be completed by the last quarter of 2002 year, says Roche, whereafter Nippon Roche and Chugai will merge. The spin-off of San Diego-based Gen-Probe will take place prior to completion of the merger. Chugai will keep its name, but be known as a "member company of Roche".